RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation. In today’s announcement, RoosterBio announced that it has entered into a Cooperative Research and Development Agreement (CRADA) that will enable “collaborative development of innovative stem cell-based therapies related to wounded warrior injuries and rehabilitation.” [Read more…]
In news released today, RoosterBio announced the “commercial launch of a new xeno-free version of their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium.” RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
Mesenchymal stem cells (MSC) are now more frequently cited than any other stem cell type within the scientific literature and Google Trend data shows MSC searches to be approximately twice as common as the next most common adult stem cell type. As a result of increases in MSC research frequency, it is important that companies like RoosterBio develop products to support efficient research processes.
To learn more, view our recent interview with Jon Rowley, RoosterBio’s CEO, or read the full press release issued by RoosterBio.
Designed by RoosterBio Inc: New Xeno-free Cell Culture Media Product Developed to Accelerate Manufacturing and Commercialization of Adult Stem Cell Products
Highly efficient bioprocess media systems provide engineered solutions for rapid product development, manufacturing scale up and industrialization of stem cells.
FREDERICK, MD (PRWEB) JUNE 13, 2016 — RoosterBio Inc. announces the commercial launch of a new xeno-free version of their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This xeno-free media formulation extends RoosterBio’s portfolio of bioprocess media engineered to streamline culture processes, minimize processing time, significantly decrease production costs, reduce regulatory burden and simplify the transition into scalable platforms for clinical and commercial adult stem cell manufacturing. [Read more…]
Without question, some of BioInformant’s most popular content has been our exclusive interviews with stem cell executives and key opinion leaders (KOL). Highlighted below are six of our most popular interviews. Enjoy! [Read more…]
The stem cell sector is fueled by innovation and rapid change. To keep you up-to-date, we recently released new coverage of the industry. Check it out and let us know what you think! [Read more…]
This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in decades-old science, that are holding the field back. [Read more…]